Page last updated: 2024-10-24

regulation of lysosomal protein catabolic process

Definition

Target type: biologicalprocess

Any process that modulates the frequency, rate or extent of lysosomal protein catabolic process. [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie, PMID:23499937]

The lysosomal protein catabolic process, or lysosomal degradation, is a vital cellular pathway responsible for the breakdown of proteins and other macromolecules within lysosomes. These organelles act as the "recycling center" of the cell, breaking down unwanted or damaged components to provide building blocks for new cellular structures. Here's a detailed breakdown of the process:

1. **Protein Targeting and Transport:** The process begins with proteins destined for lysosomal degradation. These proteins can be either misfolded, damaged, or simply short-lived. They are tagged with a specific signal known as a "lysosomal targeting signal," typically a short sequence of amino acids. This signal allows for recognition and binding by chaperone proteins, which guide the proteins to lysosomes.

2. **Endocytosis and Autophagy:** There are two main pathways for delivering proteins to lysosomes:

* **Endocytosis:** In this pathway, extracellular materials, including proteins, are taken up by the cell through invagination of the plasma membrane, forming vesicles. These vesicles then fuse with early endosomes, which mature into late endosomes. Finally, late endosomes fuse with lysosomes, delivering their contents for degradation.
* **Autophagy:** This pathway involves the engulfment of cellular components, including proteins, within double-membrane structures called autophagosomes. Autophagosomes then fuse with lysosomes, delivering the cargo for breakdown.

3. **Lysosomal Lumen:** Inside the lysosomal lumen, a highly acidic environment (pH 4.5-5.0) is maintained by proton pumps. This acidic environment is crucial for the activity of the hydrolytic enzymes present within the lysosomes. These enzymes include proteases, nucleases, lipases, glycosidases, and phosphatases, each specialized for breaking down specific types of macromolecules.

4. **Protein Degradation:** Proteases, the protein-degrading enzymes, are responsible for breaking down proteins into their constituent amino acids. These amino acids can then be reused for protein synthesis, energy production, or other cellular processes.

5. **Regulation of Lysosomal Degradation:** The regulation of lysosomal degradation is critical for maintaining cellular homeostasis and preventing accumulation of damaged or unnecessary components. This regulation involves:

* **Signal-mediated Targeting:** The presence of lysosomal targeting signals on proteins ensures efficient delivery to lysosomes.
* **Autophagy Induction:** Autophagy is induced under stress conditions, such as starvation or nutrient deprivation, to provide essential building blocks for survival.
* **Lysosomal Enzyme Activity:** The activity of lysosomal enzymes is tightly regulated by pH, substrate availability, and specific inhibitors.
* **Lysosomal Biogenesis:** The number and size of lysosomes are dynamic and can change based on cellular needs.

6. **Outcome:** The breakdown products of protein degradation, including amino acids and other molecules, are transported out of lysosomes and utilized by the cell. This process ensures the efficient recycling of cellular components and contributes to overall cellular health and function.

7. **Dysregulation and Disease:** Disruptions in lysosomal degradation can lead to a range of diseases, known as lysosomal storage disorders (LSDs). These disorders result from deficiencies in specific lysosomal enzymes, leading to the accumulation of undigested substrates within lysosomes. This buildup can cause cell dysfunction and damage, leading to a variety of clinical symptoms.

In summary, the lysosomal protein catabolic process is a complex and highly regulated pathway that plays a critical role in maintaining cellular homeostasis. This process ensures the efficient breakdown and recycling of cellular components, promoting cellular health and function. However, disruptions in this pathway can lead to various disease states, highlighting the importance of proper lysosomal function.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Lysosomal acid glucosylceramidaseA lysosomal acid glucosylceramidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P04062]Homo sapiens (human)

Compounds (40)

CompoundDefinitionClassesRoles
ambroxolAmbroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.aromatic amine
beta-glucono-1,5-lactonebeta-glucono-1,5-lactone: structure

D-glucono-1,5-lactone : An aldono-1,5-lactone obtained from D-gluconic acid.
aldono-1,5-lactone;
gluconolactone
animal metabolite;
mouse metabolite
1-deoxynojirimycin1-deoxy-nojirimycin: structure in first source

duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.
2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid
anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
miglustatmiglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.

miglustat: a glucosylceramide synthase inhibitor
piperidines;
tertiary amino compound
anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
n-phenylphthalimideN-phenylphthalimide: structure given in first source
N-Benzylphthalimideisoindoles
1-(10h-phenothiazin-2-yl)ethanone1-(10H-phenothiazin-2-yl)ethanone: structure in first sourcephenothiazines
mor-14N-methyldeoxynojirimycin: glucosidase inhibitorhydroxypiperidine;
piperidine alkaloid;
tertiary amino compound
anti-HIV agent;
cardioprotective agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite
1,2,3,4-tetrahydroxy-nor-tropanecalystegine B(2): RN given for (2-endo,3-exo,4-endo)-isomer; structure in first source
homonojirimycinhomonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source
cyclophellitolcyclophellitol: structure given in first source; isolated from Phellinus sp.
calystegine a3calystegine A3: also inhibits beta-xylosidase; structure in first source
miglitolpiperidines
isofagominepiperidines
n-nonyl-1-deoxynojirimycinN-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group.hydroxypiperidine;
tertiary amino compound
antiviral agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.2.1.45 (glucosylceramidase) inhibitor
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanolbenzimidazoles
2-(2-phenylethylthio)-3-pyridinecarboxylic acidaromatic carboxylic acid;
pyridines
4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thionebenzenes
2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanoldialkylarylamine;
tertiary amino compound
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamidesulfonamide
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxidearomatic ether
2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanoldialkylarylamine;
tertiary amino compound
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amineN-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine : A member of the class of quinazolines that is quinazoline which is substituted by a pyridin-3-yl group and a (1-benzylpiperidin-4-yl)nitrilo group at positions 2 and 4, respectively.aromatic amine;
piperidines;
pyridines;
quinazolines;
secondary amino compound;
tertiary amino compound
N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamideaminoquinoline
n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin
ogt2378sinbaglustat: an antineopl agent; structure in first source
nnc 26-9100NNC 26-9100: structure in first sourceaminopyridine
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolaromatic ether
2-[[4-(5-chloro-2-methoxyanilino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]ethanolmethoxybenzenes;
substituted aniline
2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanoldialkylarylamine;
tertiary amino compound
2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanoldialkylarylamine;
tertiary amino compound
2-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolmethoxybenzenes;
substituted aniline
2-[[4-(3-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolmethoxybenzenes;
substituted aniline
2-[[4-(4-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolmethoxybenzenes;
substituted aniline
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenoldialkylarylamine;
tertiary amino compound
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolaromatic ether
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanolaromatic ether
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolaromatic ether
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanolaromatic ether